[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cd33-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CD33 Gene",12,11,[8,16,22,29,35,41,47,53,59,65,71,77],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05945849","CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory\u002FRelapsed AML",[12],"Phase 1","RECRUITING","2026-08-26T02:18:02.701182Z","2026-07-19T19:36:05.121751Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06714591","Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1",[12],"2026-08-26T02:16:50.548894Z","2026-07-05T05:32:16.691656Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06917911","Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)",[26],"Phase 2","2026-08-26T02:18:51.009190Z","2026-05-29T15:36:40.176459Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06419634","Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",[12],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:29.152384Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT00801489","Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[26],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:28.539567Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05672147","CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia",[12],"2026-08-26T02:18:45.196599Z","2026-05-05T02:43:28.534301Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05558124","CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML",[12],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:28.122988Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT03737955","Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia",[26],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.759414Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT05105152","PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML",[12],"2026-08-26T02:15:17.167444Z","2026-05-05T02:43:27.056269Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT04050280","CLAG-GO for Patients With Persistent, Relapsed or Refractory AML",[26],"2026-08-26T02:16:21.385056Z","2026-05-05T02:43:26.745461Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT05886049","A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated\u002FFLT3 Wildtype or MLL\u002FKMT2A Rearranged or NUP98 Alterations Disease",[12],"2026-08-26T02:19:05.360997Z","2026-07-05T05:32:16.737825Z",{"nct_id":78,"title":79,"phases":80,"status":82,"updated_at":83,"content_modified":84},"NCT07026942","Phase I\u002FII Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML",[81],"Phase 1\u002FPhase 2","NOT_YET_RECRUITING","2026-08-26T02:17:12.307088Z","2026-05-05T02:43:27.748708Z"]